How to Register Digital Therapeutics in China: 2026 Guide for Foreign Brands
Digital therapeutics (DTx) in China are software-based therapeutic interventions that must be registered as medical devices with the National Medical Products Administration (国家药品监督管理局, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú). As of 2026, foreign brands seeking to bring their digital therapeutics to the Chinese market face a rigorous process that typically takes 18 to 30 months from application submission to approval. The China market for digital therapeutics is projected to reach ¥120 billion (approximately $16.5 billion) by 2026, up from ¥45 billion in 2023, representing a compound annual growth rate of more than 36%. This guide provides a comprehensive roadmap for foreign companies navigating the NMPA registration process, including classification, clinical evidence requirements, regulatory pathways, and common pitfalls to avoid.
What Are Digital Therapeutics and How Does China Define Them?
The NMPA defines digital therapeutics (数字疗法, shùzì liáofǎ) as software-based products that deliver evidence-based therapeutic interventions to prevent, manage, or treat a medical disorder or disease. Unlike general wellness apps, DTx products in China must meet the regulatory requirements for medical devices, specifically as software medical devices (医疗器械软件, yīliáo qìxiè ruǎnjiàn). The NMPA categorizes DTx products into Class II (moderate risk) and Class III (high risk) based on their intended use and potential risk to patients.
Class II DTx products include software that provides behavioral therapy, cognitive training, or lifestyle management for chronic conditions such as type 2 diabetes, hypertension, or insomnia. Class III DTx products involve software that uses artificial intelligence (AI) to make therapeutic decisions, adjusts treatment parameters automatically, or diagnoses and treats mental health conditions such as major depressive disorder or anxiety disorders. As of mid-2025, only 14 DTx products had received NMPA approval, with 9 being Class II and 5 being Class III. This small number underscores both the opportunity and the challenge for foreign entrants.
Foreign brands must understand that the NMPA views DTx primarily as medical devices, not as software applications. This classification triggers compliance with the Medical Device Registration Regulation (医疗器械注册管理办法, yīliáo qìxiè zhùcè guǎnlǐ bànfǎ), which mandates clinical evaluation, quality system audits, and post-market surveillance. The NMPA also requires that DTx products be hosted on domestic servers located in mainland China, which typically necessitates a local entity structure such as a wholly foreign-owned enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) to hold the registration and manage data sovereignty.
The Regulatory Pathway: NMPA Classification and Registration
The NMPA registration process for digital therapeutics follows a structured pathway that foreign brands must navigate step by step. The first critical decision is determining the correct class of your product, as this determines the registration route, timeline, and clinical evidence requirements. Misclassification can result in months of delay and significant additional costs.
Step 1: Product Classification and Pre-submission Meeting
Before beginning formal registration, foreign brands should request a pre-submission meeting with the NMPA Center for Medical Device Evaluation (医疗器械技术审评中心, yīliáo qìxiè jìshù shěnpíng zhōngxīn) to confirm the classification of their DTx product. This meeting costs approximately ¥10,000 to ¥30,000 (about $1,400 to $4,200) for preparation and translation of technical documents, and it can save 3 to 6 months of wasted effort if the product is reclassified mid-process. During the meeting, you must present a technical description, intended use statement, and risk analysis to support your classification choice.
Class II products follow a simpler registration path that takes 12 to 18 months from submission to approval, with clinical evaluation requirements that may be satisfied by literature review or existing clinical data under certain conditions. Class III products require 18 to 30 months and mandatory clinical trials conducted in China, unless the product has already received approval from a comparable regulatory authority such as the US FDA or EU MDR, in which case a simplified clinical evaluation pathway may apply.
Step 2: Technical Documentation and Quality Management System
Once the product class is confirmed, you must prepare a full technical file compliant with the NMPA Medical Device Registration Application Document Requirements (医疗器械注册申请材料要求, yīliáo qìxiè zhùcè shēnqǐng cáiliào yāoqiú). This includes software design specifications, system architecture diagrams, algorithm validation reports, cybersecurity documentation, and a risk management report following ISO 14971 standards. The NMPA requires that all documentation be submitted in Chinese, with notarized translations of original English documents.
Foreign brands must also establish a quality management system (QMS) that meets the NMPA Medical Device Quality Management System Guidelines (医疗器械质量管理体系指南, yīliáo qìxiè zhìliàng guǎnlǐ tǐxì zhǐnán), which align closely with ISO 13485 but include China-specific requirements such as product traceability and adverse event reporting. If you do not have a physical presence in China, you must appoint a local agent (中国代理人, zhōngguó dàilǐ rén) who will hold the registration certificate and be responsible for post-market compliance. The local agent is typically a WFOE or a licensed Shanghai-based medical device registration service provider.
Step 3: Clinical Evaluation and Trials
Clinical evidence is the most demanding part of the registration process. For Class II DTx products, the NMPA accepts clinical evaluation reports based on: (1) literature review and clinical data from comparable devices, (2) existing clinical data from overseas registrations such as FDA or CE, or (3) a small-scale local clinical trial with 100 to 300 patients. Class III products require a full-scale clinical trial conducted in China at NMPA-recognized hospitals, typically involving 200 to 1,000 patients depending on the condition and endpoints. The cost of a China clinical trial for DTx ranges from ¥5 million to ¥20 million ($700,000 to $2.8 million), with timelines of 6 to 18 months from trial initiation to final report.
The NMPA has specific requirements for DTx clinical trials that differ from traditional drug or hardware device trials. Key considerations include: software version control (you must lock the software version for the trial), patient interaction data logging (every user action must be recorded for audit), and a data security plan that complies with China’s Personal Information Protection Law (个人信息保护法, gèrén xìnxī bǎohù fǎ). The clinical trial protocol must be approved by the NMPA before enrollment begins, and an independent ethics committee at each trial site must also provide approval.
Market Access and Reimbursement Considerations
Even after NMPA registration, foreign brands must navigate China’s complex market access environment to achieve commercial success. Without a clear market access strategy, a registered DTx product may struggle to reach patients and generate revenue. The Chinese healthcare system is still developing reimbursement mechanisms for digital therapeutics, but progress is accelerating.
As of early 2026, only 4 out of the 14 approved DTx products have been included in provincial medical insurance reimbursement catalogs. These products cover the treatment of myopia in children (e.g., visual training software), type 2 diabetes management (lifestyle intervention software), and insomnia therapy (cognitive behavioral therapy software). The inclusion process typically requires 12 to 24 months of post-market data collection and negotiations with provincial medical insurance bureaus. Foreign brands should budget ¥2 million to ¥5 million ($280,000 to $700,000) for market access activities, including health economics studies, real-world evidence generation, and payer negotiations.
Another critical pathway is hospital procurement through public tenders (招标, zhāobiāo) and direct hospital listings. DTx products that are classified as medical devices must be listed on provincial medical device procurement platforms before hospitals can purchase them. This listing process takes 3 to 6 months per province and requires pricing approval from the local Health Commission. Foreign brands should target tier-1 cities such as Beijing, Shanghai, and Guangzhou first, where hospitals have larger digital health budgets and more receptivity to DTx innovation.
Data localization is a major operational consideration. The NMPA requires that all patient data generated by DTx products be stored on servers located in mainland China. Foreign brands must establish a data center arrangement through a Chinese cloud provider such as Alibaba Cloud, Tencent Cloud, or AWS China (operated by Sinnet). The cost of data infrastructure runs from ¥500,000 to ¥1.5 million annually ($70,000 to $210,000) depending on data volume and compliance requirements. Failure to maintain data localization can result in suspension of the registration certificate and fines of up to ¥10 million ($1.4 million) under the Personal Information Protection Law.
Decision Framework: Choosing the Right Registration Path
If your DTx product is a low-risk behavioral intervention that does not use AI for treatment decisions and does not diagnose a medical condition, choose the Class II registration pathway. This path allows for a faster timeline (12–18 months), lower clinical costs (¥1 million to ¥5 million), and fewer post-market obligations. If your DTx product uses AI to adjust treatment parameters, diagnoses a disease, or treats a serious mental health condition such as major depression, choose the Class III registration pathway. This path requires a full China clinical trial (18–30 months, ¥5 million to ¥20 million) and more rigorous post-market surveillance, but it also creates a higher barrier to entry for competitors.
For foreign brands with limited China market experience, a hybrid approach is recommended: first register a Class II DTx product for a low-risk condition to establish your regulatory presence and local team, then expand to Class III products once you have accumulated China clinical data and payer relationships. This phased strategy reduces upfront risk and accelerates time to revenue by 12 to 18 months compared to attempting a Class III registration from the start.
Comparison: NMPA Registration Pathways for DTx Products
| Criterion | Class II DTx (Moderate Risk) | Class III DTx (High Risk) |
|---|---|---|
| Examples | Insomnia CBT software, diabetes lifestyle app, ADHD cognitive training | AI-driven depression treatment, adaptive insulin dosing software, diagnostic decision support |
| Registration timeline | 12–18 months | 18–30 months |
| Clinical evidence | Literature review + optional small trial (100–300 patients) | Full China clinical trial (200–1,000 patients) |
| Clinical cost (RMB) | ¥1 million – ¥5 million | ¥5 million – ¥20 million |
| QMS audit | Document review only | On-site audit of manufacturing facility and local agent |
| Post-market surveillance | Annual reports, adverse event reporting | Semi-annual reports, mandatory registry, periodic safety updates |
| Reimbursement potential | Provincial insurance (12–24 months post-launch) | National or provincial insurance (18–36 months post-launch) |
| Key regulatory standard | NMPA Software Medical Device Standard (YY/T 0664) | NMPA AI Medical Device Guidelines (2025 version) |
3 Pitfalls to Avoid in Digital Therapeutics Registration
NEXT STEPS for Foreign Brands
- Conduct a pre-submission classification assessment. Before committing to any registration path, engage an NMPA-recognized medical device testing laboratory or regulatory consultant to review your product’s design and intended use. This will confirm whether you are Class II or Class III and avoid costly misclassification. Read our guide Digital Therapeutics Classification in China: Class II vs. Class III for a detailed decision process.
- Establish a China local entity and data infrastructure. Set up a WFOE in Shanghai, Shenzhen, or Hainan (where digital health pilot programs exist) to serve as your local agent and registration holder. Simultaneously, contract with Alibaba Cloud or Tencent Cloud for domestic servers. Our article Setting Up a WFOE for Digital Health Brands in China provides a step-by-step timeline and cost breakdown.
- Begin clinical trial site selection for Class III products. If your product is Class III, start identifying NMPA-recognized hospitals with digital health research experience. The top sites include Peking University Third Hospital, Shanghai Mental Health Center, and West China Hospital. See our resource Finding Clinical Trial Sites for Digital Therapeutics in China for a complete hospital list and site coordination process.
These three actions, taken in parallel, can reduce your overall registration timeline by 6 to 9 months and lower your upfront costs by eliminating common early-stage mistakes.
— China Gateway 360 —
Remote China market entry support, built around execution.
